Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2024; 30(28): 3452-3455
Published online Jul 28, 2024. doi: 10.3748/wjg.v30.i28.3452
Published online Jul 28, 2024. doi: 10.3748/wjg.v30.i28.3452
Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinoma
Daniele Ferraro, Federica Falaschi, Luca Nazzaro, Giovanni Vennarecci, Hepato-biliary and Liver Transplant Centre, Department of General Surgery and Woman’s Health, AORN Antonio Cardarelli, Naples 80131, Italy
Author contributions: Ferraro D, Falaschi F, Nazzaro L, and Vennarecci G equally contributed to the study design, research, data analysis, writing, and revision of the letter; and all authors read and approved the final version of the manuscript.
Conflict-of-interest statement: We declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Daniele Ferraro, MD, Consultant in HPB Surgery and Liver Transplantation, Hepato-biliary and Liver Transplant Centre, Department of General Surgery and Woman’s Health, AORN Antonio Cardarelli, Naples 80131, Italy.
Received: April 29, 2024
Revised: May 28, 2024
Accepted: July 2, 2024
Published online: July 28, 2024
Processing time: 86 Days and 5.7 Hours
Revised: May 28, 2024
Accepted: July 2, 2024
Published online: July 28, 2024
Processing time: 86 Days and 5.7 Hours
Core Tip
Core Tip: The field of treatment for hepatocellular carcinoma is constantly evolving due to the advances in highly effective chemotherapeutic regimens. The possible use of drugs in the neoadjuvant setting as a powerful downstaging tool opens up the possibility of liver transplantation or liver resection for patients once deemed incurable. The use of these drugs in the adjuvant therapy setting could reinforce the results of surgery in the treatment of hepatocellular carcinoma.